Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

CAN SURGICAL INTERVENTION BE AVOIDED USING VISCOSUPPLEMENTATION THERAPY IN OSTEOARTHRITIS OF THE KNEE JOINT?



Abstract

Aims: To ascertain the efficacy of viscosupplementation with Supartz intra-articular knee injections when used in the absence of a specific protocol for its use.

Methods: Retrospective cohort study using data from a dedicated injection clinic, patient case notes and knee radiographs. Patients received the therapy in the absence of a protocol for its use. Patient’s age, gender, symptoms, walking ability, presence of deformity, medication history, previous injection or surgical intervention, physiotherapy, co-morbidity, date of presentation, delivery of course of supartz injections and indication were recorded. Knee radiographs were analysed using Kellgren and Lawrence grading system. Pain relief and avoidance of surgical intervention (when surgery was an option) were the outcome measures.

Results: 965 intra-articular injections in 193 courses of supartz therapy were given in 143 patients. 45.6% were male and 54.4% were female patients. At presentation, 33.2% patients were able to walk < 1/2 a mile, 35.2% patients 1/2-1 mile and 31.6% > 1 mile. Radiological assessment (using Kellgren and Lawrence grading) showed 2 cases with stage 1 disease, 83(43%) with stage 2, 102(52.3%) with stage 3, and 6 cases with stage 4 disease. The medial compartment was involved in 185 cases (95.9%), the lateral compartment in 44 (22.8 %) and patellofemoral joint (PFJ) was involved in 122 (63.2 %).

Pain relief was obtained in 84/193 cases (43.5%). In 122 cases where the aim was to avoid surgery, this was achieved in 52 cases (42.6%). Success rate decreased with increasing severity of disease (Fisher’s Exact test; p< 0.01). Only 25/122 cases with PFJ involvement had pain relief (21%), compared to 59/71 cases without PFJ involvement (83%), (Chi squared test; χ 2(1)=71.57, p< 0.01). Younger age (< 60 years) is a poor prognostic factor (Chi squared test; χ2(1)= 5.86, p=0.02).

Conclusions: Younger patients and those with PFJ involvement and advanced disease are unlikely to benefit from Supartz intra-articular injection. We consider it inappropriate to use this therapy in the absence of a protocol for its use.

The abstracts were prepared by Mr Roger Smith. Correspondence should be addressed to him at the British Association for Surgery of the Knee, c/o BOA, Royal College of Surgeons of England, 35–43 Lincoln’s Inn Fields, London WC2A 3PN.